HUTCHMED (China) Limited (AIM:HCM)
273.50
+0.50 (0.18%)
Jul 31, 2025, 4:35 PM GMT+1
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
277.96K GBP
Profits / Employee
16.64K GBP
Market Cap
2.34B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,811 | -177 | -8.90% |
Dec 31, 2023 | 1,988 | -37 | -1.83% |
Dec 31, 2022 | 2,025 | 265 | 15.06% |
Dec 31, 2021 | 1,760 | 480 | 37.50% |
Dec 31, 2020 | 1,280 | 427 | 50.06% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
Oxford Nanopore Technologies | 1,382 |
Genus | 3,500 |
HUTCHMED (China) News
- 4 weeks ago - HUTCHMED to Announce 2025 Half-Year Financial Results - GlobeNewsWire
- 4 weeks ago - HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy - GlobeNewsWire
- 2 months ago - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer - Benzinga
- 3 months ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire
- 3 months ago - AIM Market Roundup: Catenai, Seeen, Hutchmed - The Armchair Trader